Acute Myeloid Leukemia in First Remission research hub

Multicenter, Phase 3 Study of Venetoclax and Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)

This study is looking at two medicines, venetoclax and azacitidine, to see if they can help people with a type of blood cancer called acute myeloid leukemia (AML) stay well after their first round of treatment. It's a key stage of research to check their safety and how well they work.